( 12 ) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY ( PCT ) . ( 19 ) W0rld Intellectual Pr0perty Organizati0n Internati0na1 Burcau. . ( 10 ) Internati0nal Publicati0n Number. . ( 43 ) Internati0nal Publicati0n Date M WO 2012 / 150520 A1 8 N0vember 2012 ( 08.11.2012 ) WI P 0 | P C T ( 51 ) Internati0nal Patent Classiﬁcati0n : ( 74 ) Agent : KLEIMAN , Gabriel L. ; Pﬁzer Inc. , 235 East. ( 21 ) . ( 22 ) . ( 25 ) . ( 26 ) ( 30 ) . ( 71 ) . ( 72 ) ( 75 ) . C07D 501 / 24 ( 2006.01 ) A61K 31 / 546 ( 2006.01 ) . A61P 3 ] / 04 ( 2006.01 ) . Internati0nal Applicati0n Number : PCT / IB2012 / 051973. Internati0nal Filing Date : . 19 Apri12012 ( 19.04.2012 ) Filing Language : Eng1ish Publicati0n Language : English Pri0rity Data : 61 / 481 , 407 2 May 2011 ( 02.05.2011 ) US Applicant 00r a11 designated States except US ) : PFIZER. INC. [ US / US ] ; 235 East 42nd Street , NeW Y0rk , NeW Y0rk 10017 ( US ) . Invent0rs ; and. Invent0rs / Applicants €0r US 0n1y ) : DUCLOS , Brian A. [ US / US ] ; 6568 Be1a AVe. , Ka1amaz00 , Michigan 49009 ( US ) . ELLSWORTH , Edmund L. [ US / US ] ; 730 U AVe. East , Vicksburg , Michigan 49097 ( US ) . EWIN , Richard A. [ GB / US ] ; 8399 Mystic Trai1 , Ka1amaz00 , Michigan 49009 ( US ) . JOHNSON , Paul D. [ US / US ] ; 7060 SOuth 10th Street , Ka1amaZ00 , Michigan 49009 ( US ) . JOHNSON , Tim0thy A. [ US / US ] ; 6178 Hidden Lake Circ1e , Richland , Michigan 49083 ( US ) . KYNE , Graham M. [ GB / US ] ; 7649 Hampt0n Oaks Dr. , P01tage , Michigan 49024 ( Us ) . SHEEHAN , Susan M. K. [ US / US ] ; 4049 Br0ken Ridge Circ1e , Ga1esburg , Michigan 49053 ( US ) . VAIRAGOUNDAR , Rajendran [ IN / U S ] ; 7606 Pas0 Fin0 Ct. , Ka1amaZ00 , Michigan 49009 ( US ) . ( 81 ) . ( 84 ) . 42nd. Street , NeW Y0rk , NY 10017 ( US ) . Designated States ( an1ess 0therwz°se tndtcated , f0r every kind 0f nati0na1 pr0tecti0n avaiZab1e ) : AE , AG , AL , AM , AO , AT , AU , AZ , BA , BB , BG , BH , BR , BW , BY , BZ , CA , CH , CL , CN , CO , CR , CU , CZ , DE , DK , DM , DO , DZ , EC , EE , EG , ES , FI , GB , GD , GE , GH , GM , GT , HN , HR , HU , lD , IL , IN , IS , JP , KE , KG , KM , KN , KP , KR , KZ , LA , LC , LK , LR , LS , LT , LU , LY , MA , MD , ME , MG , MK , MN , MW , MX , MY , MZ , NA , NG , NI , NO , NZ , OM , PE , PG , PH , PL , PT , QA , RO , RS , RU , RW , SC , SD , SE , SG , SK , SL , SM , ST , SV , SY , TH , TJ , TM , TN , TR , TT , TZ , UA , UG , US , UZ , VC , VN , ZA , ZM , ZW. Designated States ( an1ess 0therwise indiCated , f0r every kind 0fregz ' 0na1pr0tec ' ti0n avadabZe ) : ARIPO ( BW , GH , GM , KE , LR , LS , MW , MZ , NA , RW , SD , SL , SZ , TZ , UG , ZM , ZW ) , Eurasian ( AM , AZ , BY , KG , KZ , MD , RU , TJ , TM ) , Eur0pean ( AL , AT , BE , BG , CH , CY , CZ , DE , DK , EE , ES , FI , FR , GB , GR , HR , HU , IE , IS , IT , LT , LU , LV , MC , MK , MT , NL , NO , PL , PT , RO , RS , SE , SI , SK , SM , TR ) , OAPI ( BF , BJ , CF , CG , CI , CM , GA , GN , GQ , GW , ML , MR , NE , SN , TD , TG ) . Declarati0ns under Rule 4.17 : . as t0 the identity 0f the invent0r ( the 4.1 7 ( t ) ) . as t0 apph ' Cant ' s entitZement t0 app1yf0r and be granted a patent ( the 4.1 7 ( z ' i ) ) . as t0 the appZiCant ' s entit1ement t0 cJaim the pri0rz ' ty 0fthe ear1z°er appIiCati0n ( Ra1e 4.1 7 ( iti ) ) . Published : . with internati0na1 search rep0rt ( Art. 21 ( 3 ) ) . . W0 2012 / 150520 A1 |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. ( 54 ) Title : NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS. / 0Me N Nl H E R2 R1 - s / / H2N_< / fk“ %B ( I ) s 0 ) : N \ ° / \Rt ) n 0 0H. ( 57 ) Abstract : The present inVenti0n pr0Vides n0Ve1 cepha10sp0rin deriVatiVes 0f f0rmu1a ( I ) , their ana10gues , their use f0r the treat - ment 0f infecti0ns in mamma1s , pharmaceutica1 c0mp0siti0n c0ntaining these n0Ve1 c0mp0unds , and meth0ds f0r the preparati0n 0f these c0mp0unds. WO 2012 / 150520 PCT / IB2012 / 051973. NOVEL CEPHALOSPOR|NS USEFUL AS ANT|BACTER|AL AGENTS. F|ELD OF THE |NVENT|ON The present invention provides nove| cepha|osporin derivatives , their ana|ogues , their use for the treatment of infections in mamma|s , pharmaceutica| composition Containing these nove| Compounds , and methods for the preparation of these. compounds. BACKGROUND OF THE |NVENT|ON. Cepha|osporins are broad spectrum , common|y used antibacteria| agents for the treatment of bacteria| infections. The emergence and spread of resistance to second and third generation cepha|osporins is threatening to create species resistance to a|| current|y avai|ab|e agents. Resistant bacteria popu|ations are increasing because of the combined impact of the various uses of antimicrobia| drugs in humans and anima|s , inc|uding the use of expanded - spectrum cepha|osporins. |n the fie|d of anima| hea|th , particu|ar|y in food - producing anima|s , whi|e cepha|osporins are current|y used for the treatment of various infections , there are considerab|e regu|atory and pub|ic concerns around the use of second and third generation cepha|osporins due to the concern that the resistant organisms , particu|ar|y the resistant organisms of Escherichia coli , SaImonella and Camponbacter , wi|| be transferred to human hea|th as contaminants in foodstuffs. According|y , there remains a demand for a|ternative nove| cepha|osporins that have se|ective spectrum of antibacteria| efficacy to the targeted pathogens with minima| or no activity against unintended pathogens to minimize the deve|opment of resistant organisms. A pharmaceutica| or veterinary product of this nature wou|d have a minima| impact to human , anima|s and environment. The present invention provides nove| cepha|osporin derivatives that are se|ective against infections in mamma|s caused by pathogens such as Mannheimia haemolytica , Pasteurella multocida , and HistophiIus. somni. SUMMARY OF THE |NVENT|ON. The present invention provides a compound of formu|a | : . 1. WO 2012 / 150520 PCT / IB2012 / 051973. / 0Me N w H H R2 R1 : s / / H2N - <Sﬂ H H 0 / \\ ( R3 ) , | o oH. or a pharmaceutica||y acceptab|e sa|t thereof wherein : R1 is - NR4R5 , - SO2R6 , - C ( =O ) NR4R4 , —sR4 , - S ( C=O ) R4 , - S ( C=S ) R4 , - sc ( =o ) oR4 , - SC ( =O ) NHR4 , - SP ( =O ) ( OR4 ) 2 ; or R1 is - C1_8a|ky| substituted with —sR4 , —s ( c=o ) R4 , —s ( c=s ) R4 , - sc ( =o ) oR4 , - SC ( =O ) NHR4 , - SP ( =O ) ( OR4 ) 2 , - C ( =O ) NR4R5 , - SO2R6 ; or R1 is - OC1 - 8a|ky| substituted with —sR4 , - s ( c=o ) R4 , —s ( c=s ) R4 , - sc ( =o ) oR4 , - SC ( =O ) NHR4 , - SP ( =O ) ( OR4 ) 2 , - C ( =O ) NR4R5 , or - SO2R6 ; R2 and R3 are independent|y - H , - OH , - CN , ha|o , - NO2 , - C1_10a|ky| , - OC1_10a|ky| , - N ( R4 ) 2 ; or R1 and R3 taken together with the carbons to which they are attached form an ary| or heteroary| ; R4 is - H or - C1_10a|ky| ; R5 is - SO2R4 , - C ( =O ) C1_10a|ky| ; R6 is H , C1_6a|ky| , or NR4R4 ; at each occurrence , Ci - 10a|ky| is optiona||y substituted with - OH , - CN , ha|o , - NO2 , - OC1 - sa|ky| , - SH , - SC1 - 4a|ky| , - S ( C=O ) C14a|ky| , or - O ( C=O ) C1 - 4a|ky| ; and n is 1 , 2 , or 3. |n another aspect , the present invention a|so provides : . pharmaceutica| compositions which comprise a pharmaceutica||y acceptab|e carrier and a compound of formu|a | , . methods for contro||ing or treating infections in mamma|s caused by Gramnegative respiratory pathogens by administering to a mamma| in need of a therapeutica||y effective amount of a compound of formu|a | or a pharmaceutica||y acceptab|e sa|t thereof , . methods for contro||ing or treating infections in |ivestock caused by Gramnegative pathogens by administering to a mamma| in need a therapeutica||y effective. amount of a compound of formu|a | or a pharmaceutica||y acceptab|e sa|t thereof , . 2. WO 2012 / 150520 PCT / IB2012 / 051973. methods for treatment of infections in mamma| caused by Gram - negative pathogens such as Mannheimia haemolytica , PasteurelIa muItoci ' da , and Histophilus somni , . methods for treating infections in catt|e and swine caused by Gram - negative pathogens such as Mannheimia haemolyti ' ca , Pasteurella multocida , and Histophilus somni , . methods for treating bovine respiratory disease caused by Gram - negative respiratory pathogens such as Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni , . methods for treating swine respiratory disease caused by Gram - negative respiratory pathogens such as Mannheimia haemontica , PasteurelIa muItocida , and HistophiIus somni , and. methods for the preparation of compounds of the present invention. DETA|LED DESCR|PT|ON. With respect to the above compound , and throughout the app|ication and c|aims , the fo||owing terms have the meanings defined be|ow. The term “ha|o” refers to ch|oro , bromo , f|uoro , and iodo. The carbon atom content of various hydrocarbon - containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety , i. e. , the prefix CH indicates a moiety of the integer “i” to the integer “j” carbon atoms , inc|usive. Thus , for examp|e , C14 a|ky| refers to a|ky| of one to four carbon atoms , inc|usive ; Ci_6 a|ky| refers to a|ky| of one to six carbon atoms , inc|usive ; C1_8 a|kyrefers to a|ky| of one to eight carbon atoms , inc|usive ; Ci - 10 a|ky| refers to a|ky| of one to ten carbon atoms , inc|usive. The term a|ky| refers to straight , branched and a cyc|ic saturated monova|ent hydrocarbon groups , but reference to an individua| radica| such as “propyI” embraces on|y the straight chain radica| , a branched chain isomer such as “isopropyI” or a cyc|ic. isomer such as cyc|opropy|methy| or cyc|openty| being specifica||y referred to. WO 2012 / 150520 PCT / IB2012 / 051973. The term “ary|” refers to a cyc|ic or po|ycyc|ic aromatic ring having from 5 to 12 carbon atoms , and optiona||y substituted with 1 - 3 groups se|ected from - OH , - CN , ha|o , - NO2 , C1 - 4a|ky| , - OC1_6a|ky| , - SH , - SC14a|ky| , - S ( C=O ) C1_4a|ky| , or - O ( C=O ) C1_4a|ky|. The term “heteroary|” refers to an aromatic cyc|ic or po|ycyc|ic ring system having from 1 to 3 hetero atoms se|ected from N , O , and S. Heteroary| is optiona||y substituted with 1 - 3 groups se|ected from - OH , - CN , ha|o , - NO2 , Ci4a|ky| , - OC1 - 6a|ky| , - SH , - SC1 - 4a|ky| , - S ( C=O ) C1 - 4a|ky| , or - O ( C=O ) Ci - 4a|ky|. Typica| heteroary| groups inc|ude 2 - or 3 - thieny| , 2 - or 3 - furany| , 2 - or 3 - pyrro|y| , 2 - , 4 - , or 5 - imidazo|y| , 3 - , 4 - , or 5 - pyrazo|y| , 2 - , 4 - , or 5 - thiazo|y| , 3 - , 4 - , or 5 - isothiazo|y| , 2 - , 4 - , or 5 - oxazo|y| , 3 - , 4 - , or 5 - isoxazo|y| , 3 - or 5 - 1 , 2 , 4 - triazo|y| , 4 - or 5 - 1 , 2 , 3 - triazo|y| , tetrazo|y| , 2 - , 3 - , or 4 - pyridiny| , 3 - , 4 - , or 5 - pyridaziny| , 2 - pyraziny| , 2 - , 4 - , or 5 - pyrimidiny| , 2 - , 3 - , 4 - , 5 - , 6 - , 7 - , or 8 - quino|iny| , 1 - , 3 - , 4 - , 5 - , 6 - , 7 - , or 8 - isoquino|iny| , 2 - , 3 - , 4 - , 5 - , 6 - , or 7 - indo|y| , 2 - , 3 - , 4 - , 5 - , 6 - , or 7 - benzo [ b ] thieny| , 2 - , 4 - , 5 - , 6 - , or 7 - benzoxazo|y| , 2 - , 4 - , 5 - , 6 - , or 7 - benzimidazo|y| , 2 - , 4 - , 5 - , 6 - , or 7 - benzothiazo|y|. Preferred aromatic fused heterocyc|ic rings of from 8 to 1O atoms inc|ude but are not |imited to 2 - , 3 - , 4 - , 5 - , 6 - , 7 - , or 8 - quino|iny| , 1 - , 3 - , 4 - , 5 - , 6 - , 7 - , or 8 - isoquino|iny| , 2 - , 3 - , 4 - , 5 - , 6 - , or 7 - indo|y| , 2 - , 3 - , 4 - , 5 - , 6 - , or 7 - benzo [ b ] thieny| , 2 - , 4 - , 5 - , 6 - , or 7 - benzoxazo|y| , 2 - , 4 - , 5 - , 6 - , or 7 - benzimidazo|y| , 2 - , 4 - , 5 - , 6 - , or 7 - benzothiazo|y|. The term "mamma|" refers to human or anima|s inc|uding |ivestock and companion anima|s. The phrase “companion anima|” or “companion anima|s” refers to anima|s kept as pets. Examp|es of companion anima|s inc|ude cats , dogs , and horses. The term “|ivestock” refers to anima|s reared or raised in an agricu|tura| setting to make products such as food or fiber , or for its |abor. |n some embodiments , |ivestock are suitab|e for consumption by mamma|s , for examp|e humans. Examp|es of |ivestock anima|s inc|ude mamma|s , such as catt|e , goats , horses , pigs , sheep , inc|uding |ambs , and rabbits , as we|| as birds , such as chickens , ducks and turkeys. Specifica||y , |ivestock anima|s of the present invention refer to catt|e and pigs. The term “contro||ing” , “treating" or "treatment" of a disease inc|udes : ( 1 ) preventing the disease , i. e. causing the c|inica| symptoms or signs of the disease not to deve|op in a mamma| that may be exposed to or predisposed to the disease but does. not yet experience or disp|ay symptoms / signs of the disease ; ( 2 ) inhibiting the disease , . 4. WO 2012 / 150520 PCT / IB2012 / 051973. i. e. , arresting or reducing the deve|opment of the disease or its c|inica| symptoms / signs ; or ( 3 ) re|ieving the disease , i. e. , causing regression of the disease or its c|inicasymptoms / signs. The term "therapeutica||y effective amount" means the amount of a compound that , when administered to a mamma| for treating a disease , is sufficient to effect such treatment for the disease. The "therapeutica||y effective amount" wi|| vary depending on the compound , the disease and its severity and the age , weight , etc. , of the mamma| to be treated. The term “pharmaceutica||y acceptab|e” means suitab|e for use in mamma|s , companion anima|s or |ivestock anima|s. The term “prodrug” refers to a bio - reversib|e derivative of a mo|ecu|e , i. e. a compound of formu|a | of the present invention. Prodrugs can a|ter the so|ubi|ity , |ipophi|icity and in - vivo distribution of drugs. By de|iberate|y a|tering these key properties , it may be possib|e to improve absorption , enhance onset time , reduce first pass metabo|ism , a||ow deve|opment of aqueous |V formu|ations and achieve targeted de|ivery. |n addition , prodrugs are usefu| in improving transderma| de|ivery , masking taste , minimizing pain on injection , improving stabi|ity , etc. |n situations where the pharmacophore itse|f |eads to poor de|ivery properties , prodrugs are one of the few strategies that can be used to sa|vage the high|y active compound. |nc|uded within the scope of the present invention are a|| prodrugs of the compounds of formu|a I that can be prepared by the standard methods known to one ski||ed in the art. Prodrugs of the compounds of formu|a I may be prepared fo||owing the methods described in “Prodrugs of phosphates , phosphonates , and phosphinates” , Krise JP , Ste||a VJ , Advanced Drug De|ivery Reviews , 19 : ( 2 ) 287 - 310 MAY 22 1996 ; “Targeted Prodrug Design to Optimize Drug De|ivery”. Hyo - Kyung Han and Gordon Amidon. AAPS PharmSci 2000 ; 2 ( 1 ) artic|e 6 ; “Prodrugs” , L. Prokai and K. Prokai - Tatrai , Chapter 12 in |niectab|e Druq Deve|opment : Techniques to Reduce Pain and |rritation , |nterpharm Press , Buffa|o Grove , |N , 1999 ; “|mproved ora| drug de|ivery : So|ubi|ity |imitations overcome by the use of prodrugs” , F|eisher D , Bong R , Stewart BH , Advanced Drug De|ivery Reviews , 19 : ( 2 ) 115 - 13O MAY 22 1996 ; or “Preparation and hydro|ysis of water so|ub|e , non - irritating. prodrugs of pharmaceutica|s with oxaa|kanoic acids” , . Crooks , Peter Anthony ; . 5. WO 2012 / 150520 PCT / IB2012 / 051973. Cynkowski , Tadeusz ; Cynkowska , Grazyna ; Guo , Hong ; Ashton , Pau|. PCT |nt. App|. ( 2000 ) , 65 pp. Compounds that have the same mo|ecu|ar formu|a but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". |nc|uded within the scope of the described compounds are a|| isomers ( e. g. cis - , trans - , enantiomers , or diastereomers ) of the compounds described herein a|one as we|| as any mixtures. A|| of these forms , inc|uding enantiomers , diastereomers , cis , trans , syn , anti , so|vates ( inc|uding hydrates ) , tautomers , and mixtures thereof , are inc|uded in the described compounds. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 is - NR4R5 , - SO2R6 , - C ( =O ) NR4R4 , —sR4 , - S ( C=O ) R4 , - C1 - 4a|ky| substituted with —sR4 , - S ( C=O ) R4 , - C ( =O ) NR4R5 , or - SO2R6 ; or R1 is - OC1_8a|ky| substituted with - SR4 , - S ( C=O ) R4 , - C ( =O ) NR“R5 , or - SO2R6. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 is - NR4R5 , - SO2R6 , or - C1.4a|ky| substituted with —SR4 , - S ( C=O ) R4 , - C ( =O ) NR4R5 , or - SO2R6. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 is - C1 - 4a|ky| substituted with —SR4 , - S ( C=O ) R4 , or - SO2R6. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein A compound of c|aim 1 wherein R1 a methy| substituted with —SR4 , - S ( C=O ) R4 , or - SO2R6. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 a methy| substituted with —SH , or - S ( C=O ) CH3. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 is - NHC1 - sa|ky| substituted - SH , - SC1 - 4a|ky| , or - S ( C=O ) C1 - 4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R2 is H or C1_4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I. wherein R2 is C14a|ky|. WO 2012 / 150520 PCT / IB2012 / 051973. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R3 is H , OH , or C1_6a|ky| optiona||y substituted with OH , CN , ha|o , NO2 , OC1_6a|ky| , SH , SC14a|ky| , S ( C=O ) C1_4a|ky| , or - O ( C=O ) C1 , 4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R3 is H or C1 - 4a|ky| optiona||y substituted with OH , OC1_4a|ky| , SH , or SC1_4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 is - NR4R5 , - SO2R6 , - C ( =O ) NR4R4 , —sR4 , - S ( C=O ) R4 , - C1 - 4a|ky| substituted with —SR“ , - S ( C=O ) R“ , - C ( =O ) NR4R5 , or - SO2R6 ; or R1 is - OC1_8a|ky| substituted with - SR4 , - S ( C=O ) R4 , - C ( =O ) NR4R5 , or - SO2R6 ; R2 is H or C1_4a|ky| ; and R3 is H or C14a|kyoptiona||y substituted with OH , OC1.4a|ky| , SH , or SC1_4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 is - NR4R5 , - SO2R6 , or - C14a|ky| substituted with —SR4 , - S ( C=O ) R4 , - C ( =O ) NR4R5 , or - SO2R6 ; R2 is H or C1_4a|ky| ; and R3 is H or C1_4a|ky| optiona||y substituted with OH , OC1_4a|ky| , SH , or SC1_4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 - C14a|ky| substituted with —SR4 , - S ( C=O ) R4 , or - SO2R6 ; R2 is H or C1_4a|ky| ; and R3 is H or Cr - 4a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 a methy| substituted with —SH , or - S ( C=O ) CH3 ; R2 is H or C1_4a|ky| ; and R3 is H or C14a|ky|. Specifica||y , the compounds of the present invention are compounds of formu|a I wherein R1 a methy| substituted with —SH , or - S ( C=O ) CH3 ; R2 is H or methy| ; and R3 is H or methy|. Examp|es of the present invention inc|ude : . 1 ) ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 2 ) ( 6R , 7R ) - 3 - { 4 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - . carboxy|ic acid ; . WO 2012 / 150520 PCT / IB2012 / 051973. 3 ) ( 6R , 7R ) - 3 - { 5 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 4 ) ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - . 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 5 ) ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 5 - ( hydroxymethy| ) - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 6 ) ( 6R , 7R ) - 3 - { 4 - [ ( acety|su|fany| ) methy| ] - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - . 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 7 ) ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] amino } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 8 ) ( 6R , 7R ) - 3 - ( 5 - { [ ( acety|su|fany| ) acety| ] amino } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 9 ) ( 6R , 7R ) - 3 - ( 4 - { [ ( acety|su|fany| ) acety| ] ( propy| ) amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - . 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 10 ) ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] ( methy| ) amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 11 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - ( 3 - { [ ( methy|su|fany| ) acety| ] amino } benzy| ) - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 12 ) ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - . carboxy|ic acid ; . WO 2012 / 150520 PCT / IB2012 / 051973. 13 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 3 - { 3 - [ propan - 2 - y| ( su|fany|acety| ) amino ] benzy| } - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 14 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 2 , 3 - dimethy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 15 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 2 , 4 - dimethy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 16 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - [ methy| ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 17 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 18 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - methoxy - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 19 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - methy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 20 ) ( 6R , 7R ) - 3 - ( 5 - { [ 2 - ( acety|su|fany| ) ethy| ] su|famoy| } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 21 ) ( 6R , 7R ) - 3 - ( 3 - { [ 2 - ( acety|su|fany| ) ethy| ] ( ethy| ) su|famoy| } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 22 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methoxy - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - . carboxy|ic acid ; . WO 2012 / 150520 PCT / IB2012 / 051973. 23 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; 24 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methy| - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; 25 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( dimethy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; 26 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - methoxy - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; 27 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - methy| - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; or 28 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methy| - 4 - ( methy|su|fony| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . The fo||owing reaction schemes i||ustrate the genera| synthetic procedures of the compounds of the present invention. A|| starting materia|s are prepared by procedures. described in these schemes or by procedures known to one of ordinary ski|| in the art. 10. WO 2012 / 150520 PCT / IB2012 / 051973. . . . . m 4 R2 oH R H N 7 H JGY _. 2\ ' “" WW w s Br / \J | / \TY + S O —r R3 Bu3Sn R3 O / —N / ci 1 2 3 o o P 1 , i H W0 N N I H quO H N I P Y / N\ 3 R2 / O , S\ P Y / H 3 R2 8 O / - : |\|r \L—Yl S O \—r / |J YOH O / / \R ‘_ O / —N / \ 3 R3 9 O o o 5 P 4 P \ d N - HN N I 2 YﬂH\ 8 R2 X S o —r / : —Y O / —N / \\JR3. 6 Hoo. As shown in Scheme | , a compound of structure ( 2 ) can be prepared from an ary|bromide ( 1 ) in a suitab|e so|vent such as tetrahydrofuran ( THF ) , in the presence of a suitab|e organo|ithium reagent such as buty||ithium and a suitab|e a|ky|tinch|oride such as tributy|tinch|oride at temperatures between - 78°C and room temperature for severahours. |n the reaction , R2 and R3 are as previous|y defined. Y is C1_8 a|ky|. A compound of structure ( 4 ) cou|d be synthesized using the Sti||e coup|ing process by reaction of a suitab|e stannane ( 2 ) with a compound of structure ( 3 ) ( prepared according the methods described in EPO416410 ) in the presence of suitab|e pa||adium cata|yst such as tris ( dibenzy|idineacetone ) dipa||adium and an appropriate phosphine |igand such as tris ( 2 - fury| ) phosphine at e|evated temperatures up to ref|ux in suitab|e dipo|ar aprotic so|vents such as THF , 1 , 4 - dioxane or N - methy| - 2 - pyrro|idone. The protection group can be any suitab|e group such as di - tert - buty| dicarbonate , para - methoxybenzy| ether , . para - nitor benzy| ether , or tripheny|methy|. 11. WO 2012 / 150520 PCT / IB2012 / 051973. A compound of structure ( 5 ) can be prepared from a compound of structure ( 4 ) by addition of a suitab|e mesy|ating reagent such as mesy| ch|oride in the presence of a suitab|e hindered base such as diisopropy|ethy|amine ( D|PEA ) or 2 , 2 , 6 , 6 - tetramethy|piperidine in a suitab|e so|vent such as dichoromethane ( DCM ) at temperatures between - 78°C and room temperature for severa| hours. A compound of structure ( 6 ) may be synthesized from a compound of structure ( 5 ) by 8 - a|ky|ation using a suitab|e nuc|eophi|e fo||owed by removing the protection group P. |n this reaction , X is SR4 or S ( C=O ) R4. Thus , compounds of structure ( 5 ) can reacted with a suitab|e nuc|eophi|e such as thioacetic acid in the presence of a suitab|e hindered base such as D|PEA or 2 , 2 , 6 , 6 - tetramethy|piperidine in an appropriate po|ar aprotic so|vent such a DMF , THF , DMSO or acetonitri|e at temperatures between O°C and room temperature for severa| hours. The protection group P can be subsequent|y removed by the procedures known to one ski||ed in the art. For examp|e , when the protecting group P is di - tert - buty| dicarbonate or para - methoxybenzy| ether , suitab|e deprotection conditions invo|ve reaction with an acid such as trif|uoroacetic acid in a so|vent such as dich|oromethane at temperatures between 0°C and room temperature for severa| hours. Scheme || i||ustrates an a|ternative method for preparing a compound of the. present invention. . . Scheme|| d —NH P N s Br KJR3 B”3S” \dR3 R5 + S / O ; —Nr£\ / c / _ / I 7 s 3 0 PO 0 r / J r" H N r0 H2NYﬂN S R2 PNY / N S R2 ”0 ) : ( ” ' —R : - <— So‘n / R4 0 N / \\i3 R5 O / TN / \\J R5 3 1o HO 0 PO 0 R. 12. WO 2012 / 150520 PCT / IB2012 / 051973. |n this reaction , R2 , R3 , R4 and R5 are as defined previous|y. P is a suitab|e protecting group known to one ski||ed in the art. As shown in Scheme || , a compound of structure ( 7 ) may be prepared by N - a|ky|ation a corresponding commercia||y avai|ab|e pheny|amine using a suitab|e e|ectrophi|e such as methy|iodide or methane su|fony| ch|oride in the presence of suitab|e meta| hydride or organo|ithium bases such as sodium hydride or buty||ithium in po|ar protic so|vents such as THF or DMF at temperatures ranging from - 78°C to room temperature. A compound of structure ( 8 ) wherein R4 is hydrogen may be prepared from a compound of structure ( 7 ) by reaction with a suitab|e stanny|ating reagent such as bistributy|tin in the presence of a suitab|e pa||adium cata|yst such as pa||adium tetrakistripheny|phosphine in a suitab|e non - po|ar so|vent such as to|uene at temperatures ranging from room temperature to ref|ux for severa| hours. A|ternative|y , the hydrogen on the amine moiety can be further substituted by condensing structure ( 8 ) with carboxy|ic acid derivatives such as commercia||y avai|ab|e acety|thiog|yco|ic acid in the presence of coup|ing agents such as O - ( 7 - Azabenzotriazo| - 1 - y| ) - N , N , N ' , N ' - tetramethy|uronium hexaf|uorophosphate and a suitab|e hindered base such as diisopropy|ethy|amine or 2 , 2 , 6 , 6 - tetramethy|piperidine in suitab|e po|ar aprotic so|vents such as DMF or THF at temperatures between O°C and ref|ux for severa| hours. Using the Sti||e coup|ing process by reaction of a suitab|e stannane ( 8 ) with a compound of structure ( 3 ) ( can be prepared according to the methods described in EP0416410 ) in the presence of suitab|e pa||adium cata|yst such as tris ( dibenzy|idineacetone ) dipa||adium and an appropriate phosphine |igand such as tris ( 2 - fury| ) phosphine at e|evated temperatures up to ref|ux in a so|vent such as THF or 1 , 4 - dioxane , or a dipo|ar aprotic so|vent such as N - methy| - 2 - pyrro|idone provides a compound of structure ( 9 ) . A compound of structure ( 10 ) of the present invention may be prepared from compounds of formu|a ( 9 ) wherein P is a suitab|e protecting group by deprotection procedures known to one ski||ed in the art. For examp|e , when the protecting group P is di - tert - buty| dicarbonate , para - methoxybenzy| ether , para - nitor benzy| ether , or. tripheny|methy| suitab|e deprotection conditions invo|ve reaction with an acid such as. 13. WO 2012 / 150520 PCT / IB2012 / 051973. trif|uoroacetic acid in a so|vent such as dich|oromethane at temperatures between 0°C and room temperature for severa| hours. Scheme ||| i||ustrates another a|ternative method for preparing a compound of the. present invention. Scheme III R2 O “2vs 9 R“ s 9 \ﬁ§=0 kJSrO _. pSCO B s V HN Br ' \ cI Bu3Sn \y HN —” ”3 n R3 3 R3 R3 3 o 11 12 HO 13 ‘s0. . 3 PO 0 14 , I NO 2N ) WN I |S| 50 ﬁf£ H—N R4 HO 0. As shown in Scheme ||| , a compound of structure ( 12 ) may be prepared by reaction of a commercia||y avai|ab|e compound ( 11 ) with a suitab|e amine derivative such as ethano|amine in a suitab|e po|ar aprotic so|vent such as THF or DMSO at temperatures ranging from - 78°C to ref|ux for severa| hours. The resu|tant su|fonamide then reacts with a suitab|e stanny|ating reagent such as bistributy|tin in the presence of a suitab|e pa||adium cata|yst such as pa||adium tetrakistripheny|phosphine in a suitab|e non - po|ar so|vent such as to|uene at temperatures ranging from room temperature to ref|ux for severa| hours. Subsequent|y , addition of a suitab|e mesy|ating reagent such as mesy| ch|oride in the presence of a suitab|e hindered base such as diisopropy|ethy|amine ( D|PEA ) or 2 , 2 , 6 , 6 - tetramethy|piperidine in a suitab|e so|vent. 14. WO 2012 / 150520 PCT / IB2012 / 051973. such as dichoromethane ( DCM ) at temperatures between - 78°C and room temperature for severa| hours provides the methane su|fony| compound ( 13 ) . A compound of structure ( 14 ) may be prepared from a compound of structure ( 13 ) by S - a|ky|ation using a suitab|e nuc|eophi|e. Thus , compounds of structure ( 14 ) can be reacted with a suitab|e nuc|eophi|e such as thioacetic acid in the presence of a suitab|e hindered base such as D|PEA or 2 , 2 , 6 , 6 - tetramethy|piperidine in an appropriate po|ar aprotic so|vent such a DMF , THF , DMSO or acetonitri|e at temperatures between 0°C and room temperature for severa| hours. Fo||owing the procedure described in Scheme II by using the Sti||e coup|ing process and deprotection condition provides a compound of the present invention ( 15 ) . Additiona||y , many of the compounds have reactive functiona| groups that genera||y need to be derivatized with a protecting group in order to avoid unwanted side reactions. For examp|e , functiona| groups such as a|coho|s , acid groups , and amines genera||y are protected whi|e a reaction is carried out at a different site in the mo|ecu|e , and then the protecting group is subsequent|y removed fo||owing the desired chemicatransformation. The use of such protecting groups may fo||ow the standard methods in organic chemistry synthesis , as described , for examp|e , in T. W. Green and P. G. Wuts , Protective Groups in Organic Synthesis , 2nd edition , New York City : John Wi|ey & Sons , 1991. Thus , for examp|e , protecting groups such as the fo||owing may be uti|ized to protect suitab|e amino , hydroxy| , and other groups of re|ated reactivity : carboxy|ic acygroups , such as formy| , acety| , trif|uoroacety| ; a|koxycarbony| groups , such as ethoxycarbony| , t - butoxycarbony| ( BOC ) , B , B , B - trich|oroethoxycarbony| ( TCEC ) , B - iodoethoxycarbony| ; ary|oxycarbony| groups , such as benzy|oxycarbony| , p - methoxybenzy|oxycarbony| , phenoxycarbony| ; tria|ky| si|y| groups , such as trimethy|si|y| and t - buty|dimethy|si|y| ( TBDMS ) ; and groups such as trity| , tetrahydropyranyL viny|oxycarbony| , o - nitropheny|su|feny| , dipheny|phosphiny| , p - to|uenesu|fony| , and benzy| may a|| be uti|ized. The protecting group may be removed , after comp|etion of the synthetic reaction of interest , by procedures known to those ski||ed in the art. For examp|e , a BOC group may be removed by acido|ysis , a trity| group by acido|ysis or hydrogeno|ysis , TBDMS by treatment with f|uoride ions , and TCEC by treatment with. zinc. 15. WO 2012 / 150520 PCT / IB2012 / 051973. Pharmaceutica| Sa|ts. The compound of formu|a I may be used in its native form or as a sa|t. |n cases where forming a stab|e nontoxic acid or base sa|t is desired , administration of the compound as a pharmaceutica||y acceptab|e sa|t may be appropriate. Pharmaceutica||y acceptab|e sa|ts of the compounds of formu|a | inc|ude the acetate , ascorbate , aspartate , benzoate , besy|ate , bicarbonate / carbonate , bisu|phate / su|phate , borate , camsy|ate , citrate , edisy|ate , etog|utarate , esy|ate , formate , fumarate , g|uceptate , g|uconate , g|ucuronate , g|ycerophosphate , hexaf|uorophosphate , hibenzate , hydroch|oride / ch|oride , hydrobromide / bromide , hydroiodide / iodide , isethionate , |actate , ma|ate , ma|eate , ma|onate , mesy|ate , methy|su|phate , naphthy|ate , 2 - napsy|ate , nicotinate , nitrate , orotate , oxa|ate , pa|mitate , pamoate , phosphate / hydrogen phosphate / dihydrogen phosphate , saccharate , stearate , succinate , tartrate , tosy|ate and. trif|uoroacetate sa|ts. Composition / Formu|ation. . Pharmaceutica| compositions of the present invention may be manufactured by processes we|| known in the art , e. g. , by means of conventiona| mixing , disso|ving , granu|ation , dragee - making , |evigating , emu|sifying , encapsu|ating , entrapping , |yophi|izing processes or spray drying. Pharmaceutica| compositions for use in accordance with the present invention may be formu|ated in conventiona| manner using one or more pharmaceutica||y acceptab|e carriers comprising excipients and auxi|iaries , which faci|itate processing of the active compound into preparations , which can be used pharmaceutica||y. Proper formu|ation is dependent upon the route of administration chosen. Pharmaceutica||y acceptab|e excipients and carriers are genera||y known to those ski||ed in the art and are thus inc|uded in the instant invention. Such excipients and carriers are described , for examp|e , in “Remingtons Pharmaceutica| Sciences” , Mack Pub. Co. , New Jersey ( 1991 ) . The formu|ations of the invention can be designed to be short - acting , fast - . re|easing , |ong - acting , extended - re|easing , or contro||ed - re|easing. Specifica||y , the. 16. WO 2012 / 150520 PCT / IB2012 / 051973. formu|ation of the invention can be an extended re|ease form. Thus , the pharmaceutica|. formu|ations can a|so be formu|ated for contro||ed re|ease or for s|ow re|ease. Dosage Pharmaceutica| compositions suitab|e for use in the present invention inc|ude. compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose , i. e. , contro| or the treatment of infections. More specifica||y , a therapeutica||y effective amount means an amount of compound effective to prevent , a||eviate or ame|iorate symptoms / signs of infections or pro|ong the surviva| of the subject being treated. The quantity of active component , which is the compound of this invention , in the pharmaceutica| composition and unit dosage form thereof , may be varied or adjusted wide|y depending upon the manner of administration , the potency of the particu|ar compound and the desired concentration. Determination of a therapeutica||y effective amount is we|| within the capabi|ity of those ski||ed in the art. Genera||y , the quantity of active component wi|| range between 0.01% to 99% by weight of the composition. Genera||y , a therapeutica||y effective amount of dosage of active component wi|| be in the range of about o.1 mg to about 2O mg / kg of body weight / day , preferab|y about 0.1 to about 5 mg / kg of body weight / day. |t is to be understood that the dosages may vary depending upon the requirements of each subject and the severity of the infections. The desired dose may convenient|y be presented in a sing|e dose or as divided doses administered at appropriate interva|s , for examp|e , as two , three , four or more sub - doses per day. A|so , it is to be understood that the initia| dosage administered may be increased beyond the above upper |eve| in order to rapid|y achieve the desired p|asma concentration. On the other hand , the initia| dosage may be sma||er than the optimum and the dai|y dosage may be progressive|y increased during the course of treatment depending on the particu|ar situation. |f desired , the dai|y dose may a|so be. divided into mu|tip|e doses for administration , e. g. , two to four times per day. 17. WO 2012 / 150520. Medica| and Veterinarv Uses. PCT / IB2012 / 051973. Compounds of the present invention provides nove| cepha|osporin antibacteria|. agents for the treatment of bovine respiratory disease infections in catt|e caused by. Gram - negative respiratory pathogens such as Mannheimia haemontica ( M. haem. ) , . Pasteurella muItocida ( P. multo ) , and Histophilus somni with |ow re|ative antibacteria|. activity against zoonotic pathogens such as Escherichia coIi ( E. coli. ) SaImonella and. Camp ylobacter. Antibacteria| Assavs. Compounds of the present invention were tested against an assortment of Gram - . negative and Gram - positive organisms using the industria| standard techniques. described in Methods for Dilution AntimicrobiaI SusceptibiIity Tests for Bacteria That grow Aerobically ; Approved 8tandard —Eighth Edition , M0 7 - A8 , VoI. 29 No. 2 RepIaces M07 - A7 Vol. 26 No. 2. The resu|ts of the eva|uation are shown in Tab|es |. The data. demonstrates very good antibacteria| activity against BRD pathogens M. haem. and P. multo , and minimized activity against E. coli. The fifth co|umn shows the E. coli. se|ectivity margin over P. multo. When comparing the activity against these iso|ates. with that of the marketed human hea|th drug of cefepime ( screened in the same pane| ) , . the exemp|ified compounds of the present invention show >200 times more se|ectivity. . . . . . . . . over E. coIi. Examp|es E. coli 25922 M haemo P. multo E. coIi / P. multocida ( ug / mL ) 43411 ( ug / mL ) 43719 ( ug / mL ) 1 16 0.06 0.03 533 2 32 0.25 0.06 533 3 32 0.25 0.125 256 4 32 0.5 0.25 128 5 32 0.125 0.06 533 6 32 0.5 0.25 128 7 16 0.06 0.06 266 8 16 0.06 0.06 266. . . . . . . . 18. . WO 2012 / 150520 PCT / IB2012 / 051973. . . . . . . . . . . . . . . . . . . . . . . . . . 9 64 0.5 0.25 256 10 32 0.125 0.06 533 11 4 0.03 0.03 133 12 8 0.03 0.06 133 13 8 0.06 0.03 266 14 16 0.06 0.03 533 15 32 0.5 O.125 256 16 16 0.03 0.03 533 17 8 0.015 0.03 266 18 16 0.08 0.06 266 19 8 8 0.008 1000 20 64 0.25 0.25 256 21 32 0.125 0.03 1066 22 64 0.125 0.25 256 23 16 0.06 0.125 128 24 4 0.008 0.015 266 25 8 0.008 0.008 1000 26 4 0.008 0.015 266 27 8 0.008 0.015 533 28 4 0.06 0.03 133. . The synthesis of compounds of the present invention is further i||ustrated by the fo||owing examp|es. The starting materia|s and various intermediates uti|ized in the examp|es may be obtained from commercia| sources , or are readi|y prepared from commercia||y avai|ab|e organic compounds , using we|| - known methods to one ski||ed in the art. EXAMPLES Examp|e 1 Preparation of ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 19. . WO 2012 / 150520 PCT / IB2012 / 051973. N. fwqu. Step 1 Preparation of [ 2 - methy| - 3 - ( tributy|stannany| ) pheny| ] methano|. Buty| |ithium ( 65.5 mL , 164 mmo| ) is added dropwise to a so|ution of ( 3 - bromo - 2 - methy|pheny| ) methano| ( 15.0g , 76.6 mmo| ) in THF ( 165 mL ) at - 78°C. After 1 hour at - 78°C tributy|tinch|oride ( 45.0 mL , 164 mmo| ) is added and the mixture brought to room temperature over a period of 3 hours then stirred for 12 hours. Saturated ammonium ch|oride ( 100 mL ) , fo||owed by water ( 100 mL ) is added at 0°C. After a||owing warming to room temperature the mixture is extracted with diethy|ether ( 3 x 100 mL ) . The combined extracts are dried over magnesium su|fate , fi|tered and the so|vent removed under reduced pressure to give the tit|e compound as an oi| , which is purified by co|umn chromatography e|uting from neat heptane to 30% ethy|acetate / heptane ( 20.5g ) : 1H NMR ( CDC|3 ) : 7. 37 - 7. 31 ( 2H ) , 7.20 - 7.17 ( 1 H ) , 4.72 ( 2H ) , 2.42 ( 3H ) , 1.57 - 1.50 ( 6H ) , 1.39 - 1.31 ( 6H ) , 1.11 - 1.07 ( 6H ) , 0.90 ( 9H ) . Step 2 Preparation of 4 - methoxybenzy| ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - { 2 - [ ( teitbutoxycarbony| ) amino ] - 1 , 3 - thiazo| - 4 - y| } - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( hydroxymethy| ) - 2 - methy|benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - . carboxy|ate. a e. o N I N U. 20. WO 2012 / 150520 PCT / IB2012 / 051973. Tris ( 2 - fury| ) phosphine ( 352mg , 1.50 mmo| ) is added to 4 - methoxybenzy| ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - { 2 - [ ( tert - butoxycarbony| ) amino ] - 1 , 3 - thiazo| - 4 - y| } - 2 - ( methoxyimino ) acety| ] amino } - 3 - ( ch|oromethy| ) - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ate ( described in EP0416410 , 5.00g , 7.67 mmo| ) in dioxane ( 75 mL ) , fo||owed by tris ( dibenzy|idineacetone ) dipa||adium ( 693mg , 0.75 mmo| ) then [ 2 - methy| - 3 - ( tributy|stannany| ) pheny| ] methano| ( 3.70g , 8.99 mmo| , Step 1 ) and the mixture heated to 75°C for 24 hours. After a||owing to coo| to room temperature , the so|vent is removed under reduced pressure to give the tit|e compound. The crude materia| is purified using co|umn chromatography e|uting from 30% ethy|acetate / heptane to neat ethy|acetate to give a so|id ( 3.16g ) ; m / z ( C| ) 738 [ M + H ] + . Step 3 Preparation of 4 - methoxybenzy| ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - { 2 - [ ( teitbutoxycarbony| ) amino ] - 1 , 3 - thiazo| - 4 - y| } - 2 - ( methoxyimino ) acety| ] amino } - 3 - ( 2 - methy| - 3 - { [ ( methy|su|fony| ) oxy ] methy| } benzy| ) - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - . carboxy|ate. yN - o. N O / N I 1 IﬂNI ' llQ o o N / O o O ; S\\”. Methanesu|fony| ch|oride ( 0.40 mL , 5.10 mmo| ) fo||owed by D|PEA ( 1.18 mL , 6.78 mmo| ) is added to an ice co|d so|ution of the product of Step 2 ( 2.50g , 3.39 mmo| ) in DCM ( 26.1 mL ) . After stirring at 0°C for 16 hours , the mixture is di|uted with ethy|acetate ( 30 mL ) , washed with water , dried over magnesium su|fate , fi|tered and the so|vent removed under reduced pressure to give the tit|e compound as a so|id ( 2.76g ) which is used in the next step without further purification. m / z ( C| ) 816 [ M + H ] + . Step 4 Preparation of 4 - methoxybenzy| ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - { 2 - [ ( teit - butoxycarbony| ) amino ] - 1 , 3 - thiazo| - 4 - y| } - 2 - . ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ate. 21. WO 2012 / 150520 PCT / IB2012 / 051973. Thioacetic acid ( 0.47 mL , 6.37 mmo| ) fo||owed by D|PEA ( 0.56 mL , 3.19 mmo| ) is added to a so|ution of the product of Step 3 ( 2.6g , 3.2 mmo| ) in DMF ( 20 mL ) at 0°C. After stirring for 1.5 hours ethy|acetate is added. The mixture is washed with water , dried over magnesium su|fate , fi|tered and the so|vent removed under reduced pressure to give the tit|e compound as a residue , which is further purified using co|umn chromatography e|uting from neat heptane to neat EtOAc to give a so|id : ( 2.3g ) ; m / z ( C| ) 796 [ M + H ] ”. Step 5 Preparation of ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. TFA ( 10 mL ) is added to a so|ution of the product of Step 4 ( 2.00g , 2.51 mmo| ) in DCM ( 20 mL ) . After 3 hours , the reaction mixture is di|uted with to|uene ( 10 mL ) , the so|vent is removed under reduced pressure and the resu|tant oi| purified using reverse phase co|umn chromatography e|uting from neat water to neat MeCN to give the tit|e compound as a pa|e ye||ow so|id ( 750mg ) . 1HNMR ( DMSO - d6 ) : 9.65 ( 1 H ) , 7.20 - 6.97 ( 3H ) , 6.78 ( 1H ) , 5.76 - 5.70 ( 1H ) , 5.18 ( 1H ) , 4.15 ( 2H ) , 3.85 ( 3H ) , 3.80 ( 2H ) . 3.37 ( 1H ) , 3.15 ( 1H ) , 2.34 ( 3H ) , 2.16 ( 3H ) . m / z ( C| ) 576 [ M + 1 ] ”. Examp|e 2 Preparation of ( 6R , 7R ) - 3 - { 4 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - . { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 22. WO 2012 / 150520 PCT / IB2012 / 051973. / N. o H2N , N I H o U ) ”I‘ ; Jo” : ” N / o Ho 0. Fo||owing the genera| procedure of Examp|e 1 , Steps 1 - 5 , and making noncritica| variations but using commercia||y avai|ab|e ( 4 - bromo - 3 - methy|pheny| ) methano| as an intermediate , the tit|e compound is obtained. ( 31mg ) 1HNMR ( DMSO - d6 ) : 9.56 ( 1H ) , 6.94 - 7.01 ( 3H ) , 6.71 ( 1H ) , 5.65 ( 1H ) , 5.11 ( 1 H ) , 3.97 ( 2H ) , 3.78 ( 3H ) , 3.66 ( 2H ) , 3.29 ( 1H ) , 3.09 ( 1H ) , 2.27 ( 3H ) , 2.13 ( 3H ) . m / z ( C| ) 576 [ M + H ] + . Examp|e 3 Preparation of ( 6R , 7R ) - 3 - { 5 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. / No l. H2N\§MH\_rs O 2r—N / S 0 1. HO O. . Fo||owing the genera| procedure of Examp|e 1 , Steps 1 - 5 , and making noncritica| variations but using commercia||y avai|ab|e 3 - Bromo - 4 - methy|benzy| a|coho| as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.63 ( 1 H ) , 7.06 ( 3H ) , 6.79 ( 1H ) , 5.71 ( 1H ) , 5.17 ( 1H ) , 4.03 ( 2H ) , 3.85 - 4.03 ( 4H ) , 3.70 ( 1H ) , 3.23 ( 2H ) , 2.33 ( 3H ) , 2.19 ( 3H ) . m / z ( C| ) 576 [ M + H ] ”. Examp|e 4 Preparation of ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 , 6 - dimethy|benzy| } - 7 - . { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 23. WO 2012 / 150520 PCT / IB2012 / 051973. / N. o. H2N\ ( / N I H SY OéFN / HO O. Fo||owing the genera| procedure of Examp|e 1 , Steps 1 - 5 , and making non - . . critica| variations but using ( 3 - bromo - 2 , 4 - dimethy|pheny| ) methano| ( described in WO10129379 ) as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.57 ( 1H ) , 7.12 ( 1H ) , 6.99 ( 1H ) , 6.77 ( 1H ) , 5.69 ( 1H ) , 5.12 ( 1 H ) , 4.13 ( 2H ) , 4.07 ( 2H ) , 3.96 ( 2H ) , 3.84 ( 3H ) , 2.93 ( 2H ) , 2.35 ( 3H ) , 2.24 ( 3H ) , 2.18 ( 3H ) . m / z ( C| ) 590 [ M + H ] ”. Examp|e 5 Preparation of ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 5 - ( hydroxymethy| ) - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - . ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic. acid NO / s O Oj ; |\ir / OH. HO O Fo||owing the genera| procedure of Examp|e 1 — Steps 2 - 5 , and making noncritica| variations but using the product of Step 3 , Examp|e 5 as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.57 ( 1H ) , 7.22 ( 1H ) , 6.77 ( 1H ) , 5.66 ( 1H ) , 5.11 ( 1H ) , 4.43 ( 2H ) , 4.13 ( 3H ) , 3.96 ( 1H ) , 2.89 ( 2H ) , 2.34 ( 3H ) , 2.16 ( 3H ) , 2.13 ( 3H ) . m / z ( C| ) 620 [ M + H ] ”. Step 1 Preparation of ( 5 - bromo - 4 , 6 - dimethy|benzene - 1 , 3 - diy| ) dimethanediy| diacetate. OY. 0. . d , . Sodium acetate ( 33.6g , 389mmo| ) is added to a so|ution of 3 - bromo - 1 , 5 - bis ( ch|oromethy| ) - 2 , 4 - dimethy|benzene ( described in WO08151288 , 54.8g , 194mmo| ) in. 24. WO 2012 / 150520 PCT / IB2012 / 051973. DMF ( 120 mL ) and the mixture heated to 80°C for 16 hours. The mixture is coo|ed to room temperature and water ( 100 mL ) added. The s|urry is fi|tered , washed with water ( 200 mL ) and dried in a vacuum over at 45oC for 48 hours to give a so|id ( 61 .4g ) . ) : 1HNMR ( DMSO - d6 ) : 7.31 ( 1H ) , 5.11 ( 4H ) , 2.37 ( 6H ) , 2.05 ( 6H ) . Step 2 Preparation of ( 5 - bromo - 4 , 6 - dimethy|benzene - 1 , 3 - diy| ) dimethano| OH. . xim. Potassium hydroxide ( 24.1g , 429mmo| ) is added to a mixture of ( 5 - bromo - 4 , 6 - dimethy|benzene - 1 , 3 - diy| ) dimethanediy| diacetate ( 61.4g , 186.4mmo| ) in methano| ( 300mL ) and the mixture heated to 50°C for 1 hour. The so|vent is removed under reduced pressure and the so|id di|uted with water ( 600 mL ) and 3N hydroch|oric acid ( 175 mL ) . The mixture is stirred for 10 minutes and the precipitate fi|tered and dried in a vacuum oven overnight to give a so|id ( 42.9g ) . ) : 1HNMR ( DMSO - d6 ) : 7.35 ( 1 H ) , 5.15 ( 2H ) , 4.50 ( 4H ) , 2.35 ( 6H ) . Step 3 Preparation of [ 3 - bromo - 5 - ( { [ tert - buty| ( dimethy| ) si|y| ] oxy } methy| ) - 2 , 4 - dimethy|pheny| ] methano| oH. Brj : %\O‘S / , r. teit - ButyIdimethy|si|y| ch|oride ( 6.15g , 408.8 mmo| ) , imidazo|e ( 3.15g , 44.9 mmo| ) and DMAP ( 0.05g , 0.41 mmo| ) are added to a so|ution of ( 5 - bromo - 4 , 6 - dimethy|benzene - 1 , 3 - diy| ) dimethano| ( 10.0g , 41 mmo| ) at room temperature and the mixture stirred for 16 hours. The mixture is di|uted with water ( 400 mL ) and extracted with ethy|acetate ( 1400 mL ) . The organics are washed with 1N hydroch|oric acid ( 200 mL ) , saturated sodium hydrogen carbonate ( 200 mL ) and dried over sodium su|fate and the so|vent removed under reduced pressure to give a wet so|id. The so|id is di|uted with heptane ( 50 mL ) , fi|tered and washed with heptane ( 10 mL ) to give a white so|id ( 3.75g ) . 1HNMR ( DMSO - d6 ) : 7.30 ( 1H ) , 5.05 ( 1H ) , 4.62 ( 2H ) , 4.40 ( 2H ) , 2.22 ( 6H ) , 0.82 ( 9H ) , 0.10 ( 6H ) . 25. WO 2012 / 150520 PCT / IB2012 / 051973. Examp|e 6 Preparation of ( 6R , 7R ) - 3 - { 4 - [ ( acety|su|fany| ) methy| ] - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. / N. o H2N , N l H o N / o Ho 0. Fo||owing the genera| procedure of Examp|e 1 , Steps 1 - 5 , and making noncritica| variations but using commercia||y avai|ab|e ( 4 - bromo - 3 , 5 - dimethy|pheny| ) methano| as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - ds ) : 9.58 ( 1H ) , 6.94 ( 2H ) , 6.78 ( 1H ) , 5.66 ( 1H ) , 5.11 ( 1H ) , 4.02 ( 2H ) , 3.92 ( 2H ) , 3.84 ( 3H ) , 2.95 ( 2H ) , 2.35 ( 3H ) , 2.21 ( 6H ) . m / z ( C| ) 590 [ M + H ] ”. Examp|e 7 Preparation of ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] amino } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - . oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. I N—O N 0 Ho o o% S\l¢O. Fo||owing the genera| procedure of Examp|e 1 , Steps 2 and 5 , and making noncritica| variations but using the product of Step 2 , Examp|e 7 as an intermediate , the tit|e compound is obtained. ( 58mg ) 1HNMR ( DMSO - ds ) 9.60 ( 1 H ) , 9.56 ( 1 H ) , 7.10 ( 1H ) , 7.04 ( 1H ) , 6.90 ( 1H ) , 6.74 ( 1H ) , 5.67 ( 1H ) , 5.12 ( 1H ) , 3.79 ( 3H ) , 3.77 ( 2H ) , 3.74 ( 1H ) , 3.32 ( 1H ) , 3.10 ( 1H ) , 2.32 ( 3H ) , 2.02 ( 3H ) . m / z ( C| ) 618.7 [ M + H ] ”. Step 1 Preparation of 2 - methy| - 3 - ( tributy|stannany| ) ani|ine. 26. WO 2012 / 150520 PCT / IB2012 / 051973. 2 - amino - 6 - bromoto|uene ( commercia||y avai|ab|e , 1.00g , 5.38 mmo| ) , bistributy|tin ( 3.86g , 6.45 mmo| ) and pa||adium tetrakistripheny|phosphine ( 0.62g , 0.54 mmo| ) were mixed together in a microwave reaction via| and heated at 120°C for 8 hours. The so|vent was removed under reduced pressure and the resu|tant b|ack oipurified using co|umn chromatography e|uting from neat heptane to neat EtOAc to give the tit|ed compound as a c|ear oi| : ( 2.51g ) m / z ( C| ) 396 [ M + H ] ”. Step 2 Preparation of S - ( 2 - { [ 2 - methy| - 3 - ( tributy|stannany| ) pheny| ] amino } - 2 - oxoethy| ) . Y4NQ5“N O E. O - ( 7 - Azabenzotriazo| - 1 - y| ) - N , N , N ' , N ' - tetramethy|uronium hexaf|uorophosphate ( 3.20g , 8.24 mmo| ) fo||owed by D|PEA ( 2.43 mL , 13.9 mmo| ) is added to a so|ution of 2 - methy| - 3 - ( tributy|stannany| ) ani|ine ( 2.51g , 6.34 mmo| ) and commercia||y avai|ab|e acety|thiog|yco|ic acid ( 0.94g , 6.97 mmo| ) in THF ( 31.7 mL ) at 0°C and the reaction. mixture is stirred for 2 hours. The mixture is di|uted with ethy|acetate , washed twice. ethanethioate. with sat. NaHCO3 , then brine , dried over magnesium su|fate , fi|tered and evaporated. The crude product is further purified using co|umn chromatography e|uting from neat heptane to neat EtOAc to give an oi|y residue : ( 2.49g ) m / z ( C| ) 512.1 [ M + H ] + . Examp|e 8 Preparation of ( 6R , 7R ) - 3 - ( 5 - { [ ( acety|su|fany| ) acety| ] amino } - 2 - . methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - . oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 27. WO 2012 / 150520 PCT / IB2012 / 051973. OY S NO / lNH N O H2N : W“ s o p O N / . HO O. Fo||owing the genera| procedure of Examp|e 7 , and making non - critica| variations but using the product of commercia||y avai|ab|e 3 - bromo - 4 - methy|ani|ine as an starting materia| , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 10.15 ( 1 H ) , 9.64 ( 1 H ) , 7.42 ( 1H ) , 7.27 ( 1H ) , 7.08 ( 1H ) , 6.79 ( 1H ) , 5.73 - 5.70 ( 1H ) , 5.14 ( 1H ) , 3.90 - 3.72 ( 7H ) . 3.32 ( 1H ) , 3.16 ( 1H ) , 2.37 ( 3H ) , 2.19 ( 3H ) . m / z ( C| ) 619 [ M + 1 ] ”. Examp|e 9 Preparation of ( 6R , 7R ) - 3 - ( 4 - { [ ( acety|su|fany| ) acety| ] ( propy| ) amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. N4 9 H2N , N I H O : WHILUY4 O HO O Fo||owing the genera| procedure of Examp|e 7 , and making non - critica| variations. but using commercia||y avai|ab|e 4 - bromo - N - propy|benzenamine , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.62 ( 1 H ) , 8.13 ( 1H ) , 7.37 ( 2H ) , 7.32 ( 2H ) , 7.16 ( 1H ) , 6.76 ( 1H ) , 6.73 ( 1H ) , 5.74 ( 1H ) , 5.20 ( 1H ) , 3.99 ( 1H ) , 3.83 ( 3H ) , 3.48 - 3.60 ( 3H ) , 3.21 ( 1H ) , 2.27 ( 3H ) , 1.39 ( 2H ) , 0.81 ( 3H ) . m / z ( C| ) 647 [ M + H ] ”. Examp|e 10 Preparation of ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] ( methy| ) amino } benzy| ) - . 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 28. WO 2012 / 150520 PCT / IB2012 / 051973. N - . H2NYMN s s o y o O NW1k / Sf HO O Fo||owing the genera| procedure of Examp|e 7 , and making non - critica| variations. but using commercia||y avai|ab|e 3 - bromo - N - methy|ani|ine , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.55 ( 1 H ) , 7.37 ( 1H ) , 7.18 - 7.26 ( 3H ) , 6.70 ( 1H ) , 5.67 ( 1H ) , 5.12 ( 1H ) , 3.87 ( 1H ) , 3.77 ( 3H ) , 3.63 ( 1H ) , 3.47 ( 1H ) , 3.10 - 3.20 ( 3H ) , 2.22 ( 3H ) . m / z ( C| ) 619 [ M + H ] + . Examp|e 11 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - ( 3 - { [ ( methy|su|fany| ) acety| ] amino } benzy| ) - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. / N , o N H2NYﬂH S N / 0 kg S\. HO O Fo||owing the genera| procedure of Examp|e 7 , and making non - critica| variations but using 3 - ( tributy|stannany| ) ani|ine ( described in WO8907097 ) and commercia||y avai|ab|e ( Methy|thio ) acetic acid , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 10.05 ( 1H ) , 9.61 ( 1H ) , 7.54 ( 1H ) , 7.45 ( 1 H ) , 7.25 ( 1H ) , 6.98 ( 1H ) , 6.77 ( 1 H ) , 5.72 ( 1H ) , 5.17 ( 1H ) , 3.94 ( 1H ) , 3.84 ( 3H ) , 3.57 ( 1H ) , 3.48 ( 1H ) , 3.25 ( 2H ) , 3.20 ( 1H ) , 2.16 ( 3H ) . m / z ( C| ) 577 [ M + H ] + . Examp|e 12 Preparation of ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] amino } benzy| ) - 7 - { [ ( 2Z ) - . 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 29. WO 2012 / 150520 PCT / IB2012 / 051973. I N , o N s o F o N / N ) ‘S O WH S 0 Ho 0 f. Fo||owing the genera| procedure of Examp|e 7 , and making non - critica| variations but using 3 - ( tributy|stannany| ) ani|ine ( described in WO07124435 ) and commercia||y avai|ab|e acety|thiog|yco|ic acid , the tit|e compound is obtained. 1HNMR ( DMSO - d5 ) : 10.05 ( 1H ) , 9.61 ( 1H ) , 7.54 ( 1H ) , 7.45 ( 1 H ) , 7.25 ( 1H ) , 6.98 ( 1H ) , 6.77 ( 1 H ) , 5.72 ( 1H ) , 5.17 ( 1H ) , 3.94 ( 1H ) , 3.84 ( 3H ) , 3.57 ( 1H ) , 3.48 ( 1H ) , 3.25 ( 2H ) , 3.20 ( 1H ) , 2.16 ( 3H ) . m / z ( C| ) 577 [ M + H ] + . Examp|e 13 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 3 - { 3 - [ propan - 2 - y| ( su|fany|acety| ) amino ] benzy| } - 5 - . thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. / N— - O HN N I H 2 me S O O ] ; NE\ / ©\N / Uﬁ SH. HO O Fo||owing the genera| procedure of Examp|e 1 , Steps 2 and 5 , and making noncritica| variations but using the product of Step 2 , Examp|e 13 as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 10.07 ( 1H ) , 9.60 ( 1H ) , 7.51 ( 1 H ) , 7.45 ( 1H ) , 7.25 ( 1H ) , 6.98 ( 1H ) , 6.76 ( 1H ) , 5.73 ( 1H ) , 5.16 ( 1H ) , 3.97 ( 1H ) , 3.81 - 3.85 ( 4H ) , 3.56 ( 1H ) , 3.47 ( 1H ) , 3.32 ( 2H ) , 3.08 ( 1H ) , 1.23 ( 6H ) . m / z ( C| ) 605 [ M + H ] ”. Step 1 Preparation of S - ( 2 - oxo - 2 - { [ 3 - ( tributy|stannany| ) pheny| ] amino } ethy| ) . ethanethioate. ) biEn , . Fo||owing the genera| procedure of Examp|e 7 , Step 2 , and making non - criticavariations but using 3 - ( tributy|stannany| ) ani|ine ( described in WO07124435 ) and. 30. WO 2012 / 150520 PCT / IB2012 / 051973. commercia||y avai|ab|e acety|thiog|yco|ic acid , the tit|e compound is obtained : ( 1 .03g ) m / z ( C| ) 498 [ M + H ] + . Step 2 Preparation of N - ( propan - 2 - y| ) - 2 - su|fany| - N - [ 3 - . ( tributy|stannany| ) pheny| ] acetamide. Visme. i M. Sodium hydroxide ( 60mg , 1.50 mmo| ) is added to a mixture of the product of Step 1 ( 500mg , 1.00 mmo| ) and isopropy| bromide ( 113pL , 1.20 mmo| ) in DMF ( 1 mL ) . After stirring at room temperature overnight , the mixture is partitioned between brine and ethy|acetate. The organic |ayer is separated , dried over magnesium su|fate and the so|vent removed under reduced pressure to give an oi|. The crude product is further purified using co|umn chromatography e|uting from neat heptane to neat EtOAc to give the tit|e compound as an oi|y residue ( 150mg ) ; m / z ( C| ) 498 [ M + H ] ”. Examp|e 14 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 2 , 3 - dimethy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. Nd 0% , .0 H N N I / ‘NH 2 1W“ 8 o y 0 N / HO O. Fo||owing the genera| procedure of Examp|e 1 , Steps 2 and 5 , and making noncritica| variations but using the product of Step 2 , Examp|e 14 as an intermediate , the tit|e compound is obtained : ( 50mg ) : 1HNMR ( DMSO - d6 ) : 9.59 ( 1H ) , 9.43 ( 1H ) , 6.91 - 6.93 ( 2H ) , 6.76 ( 1H ) , 5.70 ( 1H ) , 5.13 ( 1H ) , 3.94 ( 1H ) , 3.84 ( 3H ) , 3.74 ( 1H ) , 3.28 ( 1 H ) , 3.18 ( 1H ) , 2.92 ( 3H ) , 2.22 ( 3H ) , 2.08 ( 3H ) . m / z ( C| ) 595 [ M + H ] + . Step1 Preparation of N - ( 3 - bromo - 4 , 5 - dimethy|pheny| ) methanesu|fonamide. 31. WO 2012 / 150520 PCT / IB2012 / 051973. QwP. / S\NH. Br. Methanesu|fony| ch|orde ( 1 .15mL , 15.0 mmo| ) is added to 3 - bromo - 4 , 5 - dimethy|ani|ine ( 2.0g , 10.0 mmo| ) and pyridine ( 6.4 mL , 79.3 mmo| ) in DCM ( 40mL ) at 0°C. After warming to room tempearture the mixture is stirred for 3 hours. Water was added and the mixture washed with 6M HC|. The oganic |ayer was dried over MgSO4 , fi|tered and evaporated to give a residue , which is purified by co|umn chromatography on si|ica ge| e|uting with 15% EtOAc / heptane to give the tit|e compound : ( 1.5g ) 1HNMR ( DMSO - d6 ) : 7.28 ( 1H ) , 6.98 ( 1H ) , 6.45 ( 1H ) , 2.99 ( 3H ) , 2.31 ( 6H ) . Step 2 Preparation of N - [ 3 , 4 - dimethy| - 5 - ( tributy|stannany| ) pheny| ] methanesu|fonamide. Q P R / SwH W3§¢\ Fo||owing the genera| procedure of Examp|e 7 — Step 1 , and making non - critica|. variations but using product of Step 1 ( Examp|e14 ) , the tit|e compound is obtained : ( 0.8g ) m / z ( C| ) 486 [ M - H ] . Examp|e 15 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 2 , 4 - dimethy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. N— - O / O\‘S / O N / ‘NH WWWH S s o hh 0. Ho 0 Fo||owing the genera| procedure of Examp|e 14 , and making non - critica|. variations but using commercia||y avai|ab|e 5 - bromo - 2 , 4 - dimethy|ani|ine as an. intermediate the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.59 ( 1H ) , 8.94 ( 1 H ) , . 32. WO 2012 / 150520 PCT / IB2012 / 051973. 7.03—7.05 ( 2H ) , 6.76 ( 1H ) , 5.72 ( 1H ) , 5.15 ( 1H ) , 3. s4 ( 1 H ) , 3.83 ( 3H ) , 3.70 ( 1H ) , 3.39 ( 1H ) , 3.29 ( 1H ) , 2.92 ( 3H ) , 2.24 ( 3H ) , 2.1s ( 3H ) . m / z ( C| ) 595 [ M + H ] + . Examp|e 16 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - [ methy| ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. I NO N S o y 0. , o o N / TS\. HO O. Fo||owing the genera| procedure of Examp|e 14 and making non - criticavariations but using N - ( 3 - bromopheny| ) - N - methy|methanesu|fonamide ( described in WO06015829 ) as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.55 ( 1H ) , 7.20 - 7.31 ( 3H ) , 7.14 ( 1H ) , 6.69 ( 1H ) , 5.65 ( 1 H ) , 5.10 ( 1H ) , 3.85 ( 1H ) , 3.75 - 3.78 ( 4H ) , 3.41 - 3.54 ( 2H ) , 3.15 ( 3H ) , 2.87 ( 3H ) . m / z ( C| ) 581 [ M + H ] ”. Examp|e 17 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. I N ' 1 ' O H2NTWHrrS S 0 CU ) o N / ﬂS\. HO O Fo||owing the genera| procedure of Examp|e 14 , and making non - criticavariations but using commercia||y avai|ab|e N - ( 3 - bromopheny| ) methanesu|fonamide as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.73 ( 1H ) , 9.63 ( 1H ) , 7.26 ( 1H ) , 7.14 ( 1H ) , 7.07 ( 1H ) , 7.00 ( 1H ) , 5.72 ( 1H ) , 5.16 ( 1H ) , 3.91 ( 1 H ) , 3.85. ( 3H ) , 3.60 ( 1H ) , 3.48 ( 1H ) , 3.20 ( 1H ) , 2.99 ( 3H ) . m / z ( C| ) 580 [ M + H ] + . 33. WO 2012 / 150520 PCT / IB2012 / 051973. Examp|e 18 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - methoxy - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - . thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 4 N / N S oVo O N / N : S!\ O H. HO O Fo||owing the genera| procedure of Examp|e 14 , and making non - criticavariations but using commercia||y avai|ab|e 3 - bromo - 5 - methoxyani|ine , the tit|e compound is obtained. LCMS : m / z ( C| ) 597 ( [ M + H ] + . Examp|e 19 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - methy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. I. . N , o HN N I H 2 fmhK S o n W H Ho 0. Fo||owing the genera| procedure of Examp|e 14 , and making non - criticavariations but using commercia||y avai|ab|e 3 - bromo - 5 - methy|ani|ine , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.65 ( 1H ) , 6.95 ( 1H ) , 6.89 ( 1H ) , 6.82 ( 2H ) , 5.73 - 5.68 ( 1H ) , 5.16 ( 1H ) , 3.90 - 3.81 ( 4H ) , 3.58 ( 1H ) , 3.46 ( 1H ) , 3.21 ( 1 H ) , 2.97 ( 3H ) , 2.25 ( 3H ) . m / z ( C| ) 581 [ M + 1 ] + . Examp|e 20 Preparation of ( 6R , 7R ) - 3 - ( 5 - { [ 2 - ( acety|su|fany| ) ethy| ] su|famoy| } - 2 - . methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - . oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 34. WO 2012 / 150520 PCT / IB2012 / 051973. O SJJ\ r N HNYmN s N / O. Fo||owing the genera| procedure of Examp|e 1 , Steps 2 - 5 , and making noncritica| variations but using the product of Step 2 , Examp|e 20 as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - ds ) : 9.63 ( 1 H ) , 7.76 ( 1H ) , 7.58 ( 2H ) , 7.4 ( 1H ) , 6.76 ( 1H ) , 5.74 ( 1H ) , 5.17 ( 1H ) , 3.8 - 4.0 ( 4H ) , 3.25 ( 2H ) , 2.85 ( 4H ) , 2.3 ( 6H ) . m / z ( C| ) 669 [ M + H ] ”. Step 1 Preparation of 3 - bromo - N - ( 2 - hydroxyethy| ) - 4 - methy|benzenesu|fonamide. Bmsﬁ : \ ' / \OH. Ethano|amine ( 3.67g , 60.1 mmo| ) is added to a so|ution of commercia||y avai|ab|e 3 - bromo - 4 - methy|benzenesu|fony| ch|oride ( 13.5g , 50.1mmo| ) in THF ( 100mL ) at 0°C. After stirring for 1 hour the mixture is washed with brine , dried over magnesium su|fate , fi|tered and evaporated to give the tit|e compound : ( 12.5g ) m / z ( C| ) 295 [ M + 1 ] ”. Step 2 Preparation of N - ( 2 - hydroxyethy| ) - 4 - methy| - 3 - . ( tributy|stannany| ) benzenesu|fonamide iii / , S\ : H\ / \OH o 0. §. Fo||owing the genera| procedure of Examp|e 7 — Step 1 , and making non - criticavariations but using the product of Step 1 , Examp|e 20 as an intermediate , the tit|e compound is obtained : ( 0.72g ) m / z ( C| ) 505 [ M + H ] ”. Examp|e 21 Preparation of ( 6R , 7R ) - 3 - ( 3 - { [ 2 - ( acety|su|fany| ) ethy| ] ( ethy| ) su|famoy| } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - . 35. WO 2012 / 150520 PCT / IB2012 / 051973. ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic. acid. Fo||owing the genera| procedure of Examp|e 20 , and making non - criticavariations but using commercia||y avaiab|e 3 - bromobenzenesu|fony| ch|oride and commercia||y avai|ab|e 2 - ( Ethy|amino ) ethano| , the tit|e compound is obtained. ( 230mg ) 1HNMR ( DMSO - ds ) : 9.57 ( 1H ) , 7.5 - 7.8 ( 4H ) , 6.77 ( 1 H ) , 6.83 ( 0.3H ) , 5.75 ( 0.7H ) , 5.55 ( 0.3H ) , 5.18 ( 1 H ) , 4.28 ( 2H ) , 4.03 ( 0.7H ) , 3.84 ( 3H ) , 3.4 - 3.7 ( 4H ) , 3.17 ( 6H ) , 1.01 ( 3H ) . m / z ( C| ) 703 [ M + Na ] + . Examp|e 22 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methoxy - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. / HN N YO OgSJLH O H. - O O\. HO O Fo||owing the genera| procedure of Examp|e 14 , and making non - criticavariations but using 3 - bromo - 4 - methoxy - N - methy|benzenesu|fonamide ( described in WO05073244 ) as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d5 ) : 9.66 ( 1H ) , 7.83 - 7.36 ( 4H ) , 6.80 ( 1H ) , 5.78 - 5.72 ( 1H ) , 5.19 ( 1 H ) , 4.03 ( 1H ) , 3.85 ( 3H ) , 3.70 ( 1H ) , 3.52 ( 1H ) . 3.19 ( 1H ) , 2.41 ( 3H ) . m / z ( C| ) 567 [ M + 1 ] + . Examp|e 23 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - . ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 36. WO 2012 / 150520 PCT / IB2012 / 051973. . / HN N YO OgSJLH 2 r / H\ S 0 — ( O / —N / HO O. Fo||owing the genera| procedure of Examp|e 14 , and making non - criticavariations but using commercia||y avai|ab|e 3 - bromo - N - methy|benzenesu|fonamide as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.66 ( 1H ) , 7.83 - 7.36 ( 4H ) , 6.80 ( 1H ) , 5.78 - 5.72 ( 1H ) , 5.19 ( 1H ) , 4.03 ( 1 H ) , 3.85 ( 3H ) , 3.70 ( 1H ) , 3.52 ( 1H ) . 3.19 ( 1H ) , 2.41 ( 3H ) . m / z ( C| ) 567 [ M + 1 ] + . Examp|e 24 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methy| - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. I | O O H2N N v H O=\\SNH S o H O. HO O Fo||owing the genera| procedure of Examp|e 14 , and making non - criticavariations but using commercia||y avai|ab|e 3 - bromo - N - 4 - dimethy|benzenesu|fonamide as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.59 ( 1 H ) , 7.49 ( 1H ) , 7.33 ( 1H ) , 7.25 ( 1H ) , 6.69 ( 1H ) , 5.70 - 5.63 ( 1H ) , 5.11 ( 1H ) , 3.87 ( 1H ) , 3.76 ( 3H ) , 3.70 ( 1H ) , 3.28 ( 1H ) . 3.13 ( 1H ) , 2.32 ( 3H ) , 2.25 ( 3H ) . m / z ( C| ) 581 [ M + 1 ] + . Examp|e 25 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( dimethy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. d N \\ N O=S \ H2NYﬂN S S 0 ) : NC O HO O. WO 2012 / 150520 PCT / IB2012 / 051973. Fo||owing the genera| procedure of Examp|e 20 , and making non - criticavariations but using commercia||y avai|ab|e 3 - bromo - N , N - dimethy|benzenesu|fonamide as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.68 ( 1 H ) , 7.70 ( 1H ) , 7.64 - 7.60 ( 3H ) , 6.81 ( 1H ) , 5.77 - 5.72 ( 1H ) , 5.18 ( 1H ) , 4.04 ( 1H ) , 3.88 ( 3H ) , 3.73 ( 1H ) , 3.55 ( 1H ) . 3.20 ( 1H ) , 2.59 ( 6H ) . m / z ( C| ) 581 [ M + 1 ] + . Examp|e 26 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - methoxy - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. Fo||owing the genera| procedure of Examp|e 20 , and making non - criticavariations but using commercia||y avaiab|e 3 - bromo - 5 - methoxybenzenesu|fony| ch|oride and commercia||y avai|ab|e N - methy|amine , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.67 ( 1H ) , 7.31 ( 1H ) , 7.16 ( 1H ) , 7.11 ( 1H ) , 6.80 ( 1H ) , 5.77 - 5.71 ( 1H ) , 5.19 ( 1H ) , 3.98 ( 1H ) , 3.85 ( 3H ) , 3.81 ( 3H ) , 3.67 ( 1H ) , 3.53 ( 1H ) , 3.21 ( 1H ) , 2.42 ( 3H ) . m / z ( C| ) 597 [ M + 1 ] + . Examp|e 27 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - methy| - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. Fo||owing the genera| procedure of Examp|e 20 , and making non - criticavariations but using commercia||y avai|ab|e 3 - bromo - N , 5 - dimethy|benzenesu|fonamide as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d6 ) : 9.56 ( 1 H ) , 7.45. 38. WO 2012 / 150520 PCT / IB2012 / 051973. ( 1H ) , 7.40 ( 1H ) , 7.28 ( 1 H ) , 6.69 ( 1 H ) , 5.69 - 5.5.63 ( 1H ) , 5.10 ( 1H ) , 3.91 ( 1 H ) , 3.76 ( 3H ) , 3.53 ( 1H ) , 3.43 ( 1H ) , 3.13 ( 1H ) 2.32 ( 3H ) . m / z ( C| ) 581 [ M + 1 ] + . Examp|e 28 Preparation of ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methy| - 4 - ( methy|su|fony| ) benzy| ] - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. / NO HN N I H 00 O HO O. Fo||owing the genera| procedure of Examp|e 1 — Steps 2 and 5 , and making noncritica| variations but using the product of Step 2 , Examp|e 27 as an intermediate , the tit|e compound is obtained. 1HNMR ( DMSO - d5 ) : 9.65 ( 1H ) , 7.75 ( 1H ) , 7.69 ( 1H ) , 7.31 ( 1H ) , 6.78 ( 1H ) , 5.75 ( 1H ) , 5.21 ( 1H ) , 3.85 ( 3H ) , 4.05 - 4.40 ( 2H ) , 3.45 ( 1H ) , 3.18 - 3.24 ( 4H ) , 2.36 ( 3H ) . m / z ( C| ) 566 [ M + H ] + . Step 1 Preparation of tributy| [ 2 - methy| - 4 - ( methy|su|fony| ) pheny| ] stannane. a W S\ WS€. Fo||owing the genera| procedure of Examp|e 7 — Step 1 , and making non - criticavariations but using 1 - bromo - 2 - methy| - 4 - ( methy|su|fony| ) benzene ( described in WO08030466 ) as an intermediate , the tit|e compound is obtained : ( 4.9g ) m / z ( C| ) 461 [ M + H ] + . 39. WO 2012 / 150520 PCT / IB2012 / 051973. CLA|MS What is c|aimed is : 1. A compound of formu|a | 0Me Y H 2 R1 H N NIJ\||N ' § ' S / / 2 —<s I 0 H \ ] 0 R3 ) | 0 0H. or a pharmaceutica||y acceptab|e sa|t thereof wherein : . R1 is —NR4R5 , - SO2R6 , - c ( =o ) NR4R4 , —SR4 , - S ( C=O ) R4 , - S ( C=S ) R4 , - sc ( =o ) oR4 , - sc ( =o ) NHR4 , - SP ( =O ) ( OR4 ) 2 ; or. R1 is - C1_8a|ky| substituted with —SR4 , - s ( c=o ) R4. - s ( c=s ) R4 , - sc ( =o ) oR4. - sc ( =o ) NHR4 , - SP ( =O ) ( OR4 ) 2 , —c ( =o ) NR4R5 , —so2R6 ; or. R1 is - OC1_8a|ky| substituted with —SR4 , - S ( C=O ) R4 , - s ( c=s ) R4 , - sc ( =o ) oR4 , - sc ( =o ) NHR4 , - SP ( =O ) ( OR4 ) 2 , - c ( =o ) NR4R5 , or - SO2R6 ; . R2 and R3 are independent|y - H , - OH , - CN , ha|o , - NO2 , - C1_10a|ky| , - OC1_10a|ky| , - N ( R4 ) 2 ; or. R1 and R3 taken together with the carbons to which they are attached form an ary| or heteroary| ; . R4 is - H or - C1_10a|ky| ; . R5 is - SO2R4 , - C ( =O ) C1_10a|ky| ; . R6 is H , C1_6a|ky| , or NR4R4 ; . at each occurrence , C1 - 10a|ky| is optiona||y substituted with - OH , - CN , ha|o , - NO2 , - OC1 - 5a|ky| , - SH , - SC1 - 4a|ky| , - S ( C=O ) C14a|ky| , or - O ( C=O ) C1 - 4a|ky| ; and. n is 1 , 2 , or 3. 2. A compound of c|aim 1 wherein R1 is —NR4R5 , - SO2R6 , —c ( =o ) NR4R4 , —sR4 , . - s ( c=o ) R4 , - C1_4a|ky| substituted with —SR4 , - s ( c=o ) R4 , - c ( =o ) NR4R5 , or - SO2R6 ; or R1 is - OC1 - 8a|ky| substituted with —SR4 , —s ( c=o ) R4 , —c ( =o ) NR4R5 , or - SO2R6. 4O. WO 2012 / 150520 PCT / IB2012 / 051973. 3. A compound of c|aim 1 wherein R1 is —NR4R5 , - SO2R6 , or - C14a|ky| substituted with —sR4 , —s ( c=o ) R4 , —c ( =o ) NR4R5 , or —so2R6. 4. A compound of c|aim 1 wherein R1 - C1_4a|ky| substituted with —SR4 , - S ( C=O ) R4 , or - SO2R6. 5. A compound of c|aim 1 wherein R1 a methy| substituted with —SR4 , —s ( c=o ) R4 , or - SO2R6. 6. A compound of c|aim 1 wherein R1 a methy| substituted with —SH , or - S ( C=O ) CH3. 7. A compound of c|aim 3 wherein R1 is - NHC1_6a|ky| substituted - SH , - SC1 - 4a|ky| , or - S ( C=O ) C1_4a|ky|. 8. A compound of c|aim 1 wherein R2 is H or Ci_4a|ky|. 9. A compound of c|aim 1 wherein R2 is C1 - 4a|ky|. 10. A compound of c|aim 1 wherein R3 is H , OH , or C1 - 6a|ky| optiona||y substituted with OH , CN , ha|o , NO2 , OCi_6a|ky| , SH , SCMaIkyI , S ( C=O ) C14a|ky| , or - O ( C=O ) C1_4a|ky|. 11. A compound of c|aim 1 wherein R3 is H or C1_4a|ky| optiona||y substituted with OH , OC14a|ky| , SH , or SC14a|ky|. 12. A compound of c|aim 1 wherein R1 is —NR4R5 , - SO2R6 , —c ( =o ) NR4R4 , —sR4 , - s ( c=o ) R4. - C1_4a|ky| substituted with —sR4. - s ( c=o ) R4 , - C ( =O ) NR4R5 , or - SO2R6 ; or R1 is - OC1_8a|ky| substituted with —sR4 , - s ( c=o ) R4 , - C ( =O ) NR4R5 , or - SO2R6 ; R2 is H or C14a|ky| ; and R3 is H or C1_4a|ky| optiona||y substituted with OH , OCMa|ky| , SH , or SC1 - 4a|ky|. 41. WO 2012 / 150520 PCT / IB2012 / 051973. 13. A compound of c|aim 1 wherein R1 is —NR4R5 , - SO2R6 , or - C1 - 4a|ky| substituted with —SR4 , - S ( C=O ) R4 , - C ( =O ) NR4R5 , or - SO2R6 ; R2 is H or C1_4a|ky| ; and R3 is H or C14a|ky| optiona||y substituted with OH , OCMaIkyI , SH , or SC1_4a|ky|. 14. A compound of c|aim 1 wherein R1 - C1 - 4a|ky| substituted with —sR4 , - s ( c=o ) R4 , or - SO2R6 ; R2 is H or C1_4a|ky| ; and R3 is H or Ci4a|ky|. 15. A compound of c|aim 1 wherein R1 a methy| substituted with —SH , or - S ( C=O ) CH3 ; R2 is H or C1_4a|ky| ; and R3 is H or Ct_4a|ky|. 16. A compound of c|aim 1 wherein R1 a methy| substituted with —SH , or - S ( C=O ) CH3 ; R2 is H or methy| ; and R3 is H or methy|. 17. A compound of c|aim 1 which is. 1 ) ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 2 ) ( 6R , 7R ) - 3 - { 4 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 3 ) ( 6R , 7R ) - 3 - { 5 - [ ( acety|su|fany| ) methy| ] - 2 - methy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 4 ) ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 5 ) ( 6R , 7R ) - 3 - { 3 - [ ( acety|su|fany| ) methy| ] - 5 - ( hydroxymethy| ) - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - . azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 42. WO 2012 / 150520 PCT / IB2012 / 051973. 6 ) ( 6R , 7R ) - 3 - { 4 - [ ( acety|su|fany| ) methy| ] - 2 , 6 - dimethy|benzy| } - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - . 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 7 ) ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] amino } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 8 ) ( 6R , 7R ) - 3 - ( 5 - { [ ( acety|su|fany| ) acety| ] amino } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 9 ) ( 6R , 7R ) - 3 - ( 4 - { [ ( acety|su|fany| ) acety| ] ( propy| ) amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - . 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 10 ) ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] ( methy| ) amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 11 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - ( 3 - { [ ( methy|su|fany| ) acety| ] amino } benzy| ) - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 12 ) ( 6R , 7R ) - 3 - ( 3 - { [ ( acety|su|fany| ) acety| ] amino } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 13 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 3 - { 3 - [ propan - 2 - y| ( su|fany|acety| ) amino ] benzy| } - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 14 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 2 , 3 - dimethy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 15 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 2 , 4 - dimethy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - . ene - 2 - carboxy|ic acid ; . 43. WO 2012 / 150520 PCT / IB2012 / 051973. 16 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - [ methy| ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 17 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 18 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - methoxy - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 19 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - { 3 - methy| - 5 - [ ( methy|su|fony| ) amino ] benzy| } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 20 ) ( 6R , 7R ) - 3 - ( 5 - { [ 2 - ( acety|su|fany| ) ethy| ] su|famoy| } - 2 - methy|benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 21 ) ( 6R , 7R ) - 3 - ( 3 - { [ 2 - ( acety|su|fany| ) ethy| ] ( ethy| ) su|famoy| } benzy| ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 22 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methoxy - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 23 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; 24 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methy| - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; . 25 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - ( dimethy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; 26 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - methoxy - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - . carboxy|ic acid ; . 44. WO 2012 / 150520 PCT / IB2012 / 051973. 27 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 3 - methy| - 5 - ( methy|su|famoy| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid ; or. 28 ) ( 6R , 7R ) - 7 - { [ ( 2Z ) - 2 - ( 2 - amino - 1 , 3 - thiazo| - 4 - y| ) - 2 - ( methoxyimino ) acety| ] amino } - 3 - [ 2 - methy| - 4 - ( methy|su|fony| ) benzy| ] - 8 - oxo - 5 - thia - 1 - azabicyc|o [ 4.2.0 ] oct - 2 - ene - 2 - carboxy|ic acid. 18. A pharmaceutica| composition comprising a compound of c|aim 1 , or a. pharmaceutica||y acceptab|e sa|t thereof and a pharmaceutica||y acceptab|e carrier. 19. A method for contro||ing or treating infections in |ivestock caused by Gramnegative pathogens by administering to a mamma| in need of a therapeutica||y effective. amount of a compound of c|aim 1 or a pharmaceutica||y acceptab|e sa|t thereof. 20. A method for treatment of infections in mamma| caused by Gram - negative pathogens such as Mannheimia haemolytica , Pasteurella multocida , and Histophilus somni by administering to a mamma| in need a therapeutica||y effective amount of a. compound of c|aim 1 or a pharmaceutica||y acceptab|e sa|t thereof. 21. A method for treating infections in catt|e and swine caused by Gram - negative pathogens such as Mannheimia haemolytica , Pasteurella multocida , and Hisfophilus somni by administering to a mamma| in need a therapeutica||y effective amount of a. compound of c|aim 1 or a pharmaceutica||y acceptab|e sa|t thereof. 22. A method for treating bovine respiratory disease caused by Gram - negative respiratory pathogens such as Mannheimia haemolytica , PasteureIIa muItocida , and Histophilus somni by administering to a mamma| in need a therapeutica||y effective. amount of a compound of c|aim 1 or a pharmaceutica||y acceptab|e sa|t thereof. 23. A method for treating swine respiratory disease caused by Gram - negative. respiratory pathogens such as Mannheimia haemolytica , PasteureIIa muItocida , and. 45. WO 2012 / 150520 PCT / IB2012 / 051973. Histophilus somni by administering to a mamma| in need a therapeutica||y effective. amount of a compound of c|aim 1 or a pharmaceutica||y acceptab|e sa|t thereof. 46. |NTERNAT|ONAL SEARCH REPORT. . . |nternationa| app|ication No. PCT / IB2012 / 051973. . A. CLASS|F|CAT|ON OF SUBJECT MATTER. iEg. C07D50l / 24 A6lK3l / 546 A6lP3l / 04. According to |nternationa| Patent C|assification ( |PC ) or to both nationa| c|assification and |PC. . B. F|ELDS SEARCHED. . Minimum documentation searched ( c|assification system fo||owed by c|assification symbo|s ) . 007D A61K A61P. . Documentation searched other than minimum documentation to the extent that such documents are inc|uded in the fie|ds searched. . EPO - Internai , CHEM ABS Data , wPI Data. E|ectronic data base consu|ted during the internationa| search ( name of data base and , where practicab|e , search terms used ) . . C. DOCUMENTS CONS|DERED TO BE RELEVANT. . Category * Citation of document , with indication , where appropriate , of the re|evant passages. Re|evant to c|aim No. . X US 5 114 933 A ( BERTRANDIE ALAIN M [ FR ] ET AL ) 19 May 1992 ( 1992 - 05 - 19 ) . Abstract ; coiumn 1 , iine 64 to coiumn 2 , iine 63 ; coiumn 3 , iine 65 to coiumn 4 , iine 10 ; coiumn 14 , exampie 12. A EP 0 061 234 A2 ( BEECHAM GROUP PLC [ GB ] ) 29 September 1982 ( 1982 - 09 - 29 ) . Abstract ; ciaims ; exampies. A EP 0 295 341 A1 ( PFIZER [ PA ] ) . 21 December 1988 ( 1988 - 12 - 21 ) . Abstract ; ciaims ; exampies. A US 5 721 359 A ( DUNN MICHAEL J [ US ] ET AL ) 24 February 1998 ( 1998 - 02 - 24 ) . Ciaims ; coiumn 2 , iines 4 - 9. _ / __. . 1 , l0 , 18. 1 - 23. 1 - 23. l - 23. . . . . . . . . . . X Further documents are |isted in the continuation of Box C. X See patent fami|y annex. . * Specia| categories of cited documents : . "A" document defining the genera| state of the art which is not considered to be of particu|ar re|evance. "P" document pub|ished prior to the internationa| fi|ing date but |ater than. "T" |ater document pub|ished after the internationa| fi|ing date or priority date and not in conf|ict with the app|ication but cited to understand the princip|e or theory under|ying the invention. "E" ear|ier app|ication or patent but pub|ished on or after the internationa| uXu document of particu|ar re|evance ' the c|aimed invention cannot be WW date considered nove| or cannot be donsidered to invo|ve an inventive. "L" documentwhich may throw doubts on priority c|aim ( s ) or which is step when the document is taken a|one cited_to estab|ish the pubiication date of another citation or other "Y" document of particu|ar re|evance ' the c|aimed invention cannot be specia| reason ( as Spe° ' f ' ed ) considered to invo|ve an inventive step when the document is. "O" document referring to an ora| disc|osure , use , exhibition or other combined with one or more other such documents , such combination means being obvious to a person ski||ed in the art. . . European Patent Office , P. B. 5818 Patent|aan 2 NL - 2280 HV Rijswijk Te|. ( + 31 - 70 ) 340 - 2040 , . . . the priority date c|aimed "8t" document member of the same patent fami|y Date of the actua| comp|etion of the internationa| search Date of mai|ing of the internationa| search report 12 June 20l2 22 / 06 / 20l2 Name and mai|ing address of the |SA / Authorized officer. Fax : ( + 31 - 7o ) 340 - 3016 WW SbY‘0d 9 Th0ma S. . Form PCT / |SA / 21O ( second sheet ) ( Apri| 2005 ) . page 1 of 2. . |NTERNAT|ONAL SEARCH REPORT. . . |nternationa| app|ication No. PCT / IB2012 / 051973. . C ( C0ntinuati0n ) . DOCUMENTS CONS|DERED TO BE RELEVANT. . Category * . Citation of document , with indication , where appropriate , of the re|evant passages. Re|evant to c|aim No. . A. A , P. . . w0 2007 / 145656 A2 ( INTERVET INT BV [ NL ] ; CADY SUSAN M [ US ] ; BARBOT CAROLE [ FR ] ) . 21 December 2007 ( 2007 - 12 - 21 ) . Ciaims ; pages l - 2 , paragraphs 3 - 4 , in particuiar the formuia of cefquinome ; page 4 , paragraph 18. LEE ET AL. : "Synthesis and antibacteriai activities of novei C ( 3 ) - aminopyrimidinyi substituted cephaiosporins inciuding against respiratory tract pathogens“ , BIO0RG. MED. CHEM. LETT. , . voi. 10 , no. 18 , . 1 September 2000 ( 2000 - 09 - 0l ) , pages 2123 - 2127 , XP004208326 , . D01 : 10.1016 / S0960 - 894X ( 00 ) 00425 - X. the whoie document. "US FDA 21 CFR Part 530 : New Animai Drugs ; Cephaiosporin Drugs ; Extraiabei Animai Drug Use ; 0rder of Prohibition" , . Federai Register , Voi. 77 , No. 4 , . 6 January 2012 ( 2012 - 01 - 06 ) , pages 735 - 745 , XP55029607 , . Retrieved from the Internet : URL : http : / / www. gpo. gov / fdsys / pkg / FR - 20l2 - 0 1 - 06 / pdf / 2012 - 35. pdf. [ retrieved on 2012 - 06 - 12 ] . Cited as background information. l - 23. 1 - 23. 1 - 23. . . Form PCT / |SA / 21O ( continuation of second sheet ) ( Apri| 2005 ) . page 2 of 2. . |NTERNAT|ONAL SEARCH REPORT. |nformation on patent fami|y members. . . |nternationa| app|ication No. . . . . . . PCT / IB2012 / 051973 Patent d oooooo t Pub|ication Patent fami|y Pub|ication cited in search report date member ( s ) date US 5114933 A l9 - 05 - l992 AT ll3050 T lS - ll - l994 DE 3750673 Dl 24 - ll - l994 DE 3750673 T2 l6 - 03 - l995 JP 6330l887 A 08 - 12 - 1988 US 51l4933 A 19 - 05 - l992 EP 006l234 A2 29 - 09 - l982 EP 006l234 A2 29 - 09 - l982 JP 57l58790 A 30 - 09 - l982 US 4460582 A l7 - 07 - l984 EP 029534l Al 21 - l2 - l988 AU 569001 Bl l4 - 0l - l988 EP 029534l Al 21 - l2 - l988 JP 6004643 B l9 - 0l - l994 JP 62148489 A 02 - 07 - l987 US 5721359 A 24 - 02 - l998 AT 202l09 T 15 - 06 - 200l AU 6944l9 B2 23 - 07 - l998 AU 635l094 A 26 - 09 - l994 CA 2155322 Al lS - 09 - l994 CN lll90l6 A 20 - 03 - l996 CZ 9502290 A3 lS - 08 - 200l DE 69427469 Dl l9 - 07 - 200l DE 69427469 T2 3l - l0 - 200l DE lZ2005000055 11 23 - 02 - 2006 DK 690864 T3 17 - 09 - 200l EP 0690864 Al 10 - 0l - l996 ES 2157254 T3 l6 - 08 - 200l FI 954250 A ll - 09 - l995 GR 30365l4 T3 3l - l2 - 200l HU 222244 Bl 28 - 05 - 2003 IL lO89l0 A 28 - l0 - l999 JP 3852946 BZ 06 - l2 - 2006 JP H085075l9 A l3 - 08 - l996 LU 9l206 I2 30 - 05 - 2006 LV lZ889 B 20 - 12 - 2002 NL 300208 11 01 - 02 - 2006 N0 953564 A 07 - 1l - l995 N0 2005025 Il 05 - l2 - 2005 NZ 263002 A 20 - l2 - l996 PL 3l0556 Al 27 - l2 - l995 PT 690864 E 30 - ll - 200l RU 2l36685 Cl l0 - 09 - l999 SK lll495 A3 06 - l2 - l995 US 572l359 A 24 - 02 - l998 M0 9420505 Al 15 - 09 - l994 ZA 940l586 A 07 - 09 - l995 M0 2007l45656 A2 21 - l2 - 2007 AT 472996 T lS - 07 - 20l0 CA 2626273 Al 21 - l2 - 2007 JP 20095l3665 A 02 - 04 - 2009 US 20083l89l9 Al 25 - l2 - 2008 M0 2007l45656 A2 21 - l2 - 2007. . Form PCT / |SA / 21O ( patent fami|y annex ) ( Apri| 2005 )